PTC Therapeutics | PTCT - Cost Of Sales


PTC Therapeutics reported $15.48M in Cost of Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 2.63B
Cash and Equivalent USD 1.02B
Cost of Sales USD 15.48M
Current Assets USD 2.27B
Current Liabilities USD 627.81M
Debt USD 286.01M
EBIT USD -34.86M
EBITDA USD 971.14M
Employees 939
EPS Earnings Per Share USD -0.83
Equity Capital and Reserves USD -206.55M
Gross Profit on Sales USD 163.39M
Interest Expense on Debt USD 30.36M
Loan Capital USD 2.13B
Market Capitalization USD 4.34B
Net Income USD -64.85M
Operating Expenses USD 213.73M
Operating Profit USD -34.86M
Ordinary Share Capital USD 79.38M
PE Price to Earnings USD 6.47
Pre-Tax Profit USD -71.05M
Sales Revenues USD 178.9M
Selling and Administration Expenses USD 85.26M
Stock USD 34.06M
Trade Creditors USD 206.31M
Trade Debtors USD 196.13M

Cost Of Sales Change Date
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Daiichi Sankyo JPY 92.35B 1.99B Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Novartis USD 3.32B 95M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
PTC Therapeutics USD 15.48M 2.62M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
TG Therapeutics USD 18.94M 3.4M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025
Xencor USD 61.66M 50.95M Jun/2025